Increase in HCM-Related Economic Burden Due to Atrial Fibrillation in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Analysis of 9490 Patients
Speaker(s)
Butzner M1, Papademetriou E2, Potluri R2, Liu X2, Shreay S1
1Cytokinetics, Incorporated, South San Francisco, CA, USA, 2Putnam Associates, LLC, Boston, MA, USA
Presentation Documents
OBJECTIVES: Atrial fibrillation (AF) is common among patients with symptomatic obstructive hypertrophic cardiomyopathy (soHCM), but the burden of AF on HCM-related healthcare resource use (HCRU) and cost is unknown. Therefore, we sought to assess the economic impact of AF on patients with soHCM.
METHODS: Symphony medical and pharmacy claims data were assessed for the years 2016–2021 to identify (ICD-10 code) adult patients with treatment-naïve soHCM in the United States. We defined symptomatic as evidence of either fatigue, chest pain, syncope, dyspnea, heart failure, or palpitations within 3 months of index date and comorbid AF as AF within 3 months of index date. Unadjusted HCM-related HCRU and charges (per-person per-year [PPPY], in USD) were reported for the following categories: hospitalizations (number and length of stay); outpatient, emergency-room, or urgent-care visits; or pharmacy use.
RESULTS: Of 9490 patients with soHCM, 2681 (28.3%) had AF. Patients with AF were older (median 68 vs 63 years; p<0.0001) and more were male (48.0% vs 42.5%; p<0.0001). Among all patients, the majority were on Medicare (39%) and Commercial (19%) insurance. Patients with vs without AF averaged significantly more HCRU across all categories assessed (all p<0.05). Total HCM-related charges were greater for patients with AF vs without (mean $26,607 vs $17,202 PPPY; p<0.0001). Across all categories, HCM-related charges were greater in patients with comorbid AF, with the majority of HCM-related total charges resulting from outpatient visits ($19,863 vs $13,416; p<0.0001) and hospitalizations ($4117 vs $2027; p<0.0001).
CONCLUSIONS: In this US-based cohort of patients with soHCM, those with comorbid AF incurred significantly more HCM-related HCRU and higher costs PPPY. This suggests that comorbid AF in soHCM is associated with a greater economic burden. In patients with soHCM, better management, including novel treatments, could reduce the additional economic burden in those with comorbid AF.
Code
EE620
Topic
Economic Evaluation
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory), Rare & Orphan Diseases